Savient hit by manufacturing problems
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals said its third-party contract manufacturing organization (CMO) in Israel, Merck Biomanufacturing Network, has experienced some batch failures with the US biotech's FDA-approved chronic refractory gout drug Krystexxa (pegloticase), a PEGylated uric acid specific enzyme.